Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”

Yu Jun Wong, Sanchit Sharma, Giulia Tosetti, Xiaolong Qi, Massimo Primignani

Clin Mol Hepatol. 2023;29(1):188-190. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0408

View: 3601 Download: 69 Web of Science: 2 Crossref: 3

Original Article

Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)

Chuan Liu, Hong You, Qing-Lei Zeng, Yu Jun Wong, Bingqiong Wang, Ivica Grgurevic, Chenghai Liu, Hyung Joon Yim, Wei Gou, Bingtian Dong, Shenghong Ju, Yanan Guo, Qian Yu, Masashi Hirooka, Hirayuki Enomoto, Amr Shaaban Hanafy, Zhujun Cao, Xiemin Dong, Jing LV, Tae Hyung Kim, Yohei Koizumi, Yoichi Hiasa, Takashi Nishimura, Hiroko Iijima, Chuanjun Xu, Erhei Dai, Xiaoling Lan, Changxiang Lai, Shirong Liu, Fang Wang, Ying Guo, Jiaojian Lv, Liting Zhang, Yuqing Wang, Qing Xie, Chuxiao Shao, Zhensheng Liu, Liu Ravaioli, Antonio Colecchia, Jie Li, Gao-Jun Teng, Xiaolong Qi

Received March 22, 2024 Accepted July 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0198 [Accepted]

View: 1433 Download: 181 Crossref: 1

Correspondence

Reply to: “From invasive to intuitive: the emerging role of non-invasive models in hepatic decompensation”

Chuan Liu, Ling Yang, Hong You, Gao-Jun Teng, Xiaolong Qi

Received August 27, 2024 Accepted August 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0723 [Accepted]

View: 365 Download: 24

Letter to the Editor

Prevalence of steatotic liver disease and associated fibrosis in the general population: an epidemiological survey

Lin Guan, Xinhe Zhang, Shanghao Liu, Xiaolong Qi, Yiling Li

Received October 17, 2024 Accepted October 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0921 [Accepted]

View: 254 Download: 27

1 |

Viewed By 5097	MAFLD: How is it different from NAFLD?
Viewed By 5072	Examining the therapeutic landscape of beta-blockers in portal hypertension
Viewed By 4498	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4472	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4363	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited By 248	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 198	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 145	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 138	MAFLD: How is it different from NAFLD?
Cited By 113	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search